title: [Antiangiogenic pathways in the future].
abstract: The metastatic process comprises several steps all dependent on different factors: cell proliferation and the Raf-MEK-ERK pathway, initiation, migration and angiogenesis via VEGF and collagenases (which digest the extracellular matrix), metastatic progression in bloodstream and implantation in a target tissues via CXCR4 according to the gradient of SDF1 chemokine. At present, inhibition of VEGF by antiangiogenic the treatment results in the activation of alternative pathways and recovery of metastasis process. The future of targeted therapies will integrate alternative paths, including CXCR4/SDF1 ones.
authors.affiliation: Service d'Urologie, Hôpital Foch, 40, rue Worth, 92151 Suresnes, France. yann.neuzillet@gmail.com
authors.forename: Y
authors.initials: Y
authors.lastname: Neuzillet
authors.forename: C
authors.initials: C
authors.lastname: Delbado
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic; D015398:Signal Transduction; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A